Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Clinical pharmacology Stories

2014-02-19 12:29:05

West Liberty University Professor Predicts a Total Cost of $247.6 Million for the State WASHINGTON, Feb. 19, 2014 /PRNewswire-USNewswire/ -- The Consumer Healthcare Products Association (CHPA) today released the following statement regarding a new economic impact study conducted by Dr. Serkan Catma of West Liberty University. The study, which was supported by a grant from CHPA, examined the potential costs associated with a proposed prescription requirement for cold and allergy medicines...

2014-02-18 08:31:48

ATLANTA, Feb. 18, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today the establishment of CryoLife Asia Pacific Pte. Ltd., a wholly-owned subsidiary of CryoLife, Inc., to expand the Company's presence in the rapidly growing Asia Pacific medical device market. To support the new subsidiary, CryoLife will relocate Mr. Rich Gridley, vice president sales, Canada, Asia-Pacific,...

2014-02-17 23:22:46

FDAnews’ editors monitor and report on regulatory developments affecting device production in more than 45 nations around the world. They’ve compiled more than 150 reports highlighting changes from the past year that will keep devicemakers growing in international markets. Falls Church, VA (PRWEB) February 17, 2014 Guide to International Medical Device Regulation — 2014 Edition **FDAnews Publication** http://www.fdanews.com/IMDRM14 In medical device manufacturing, success means...

2014-02-12 16:27:03

Company will Host Conference Call on February 13, 2014 CUPERTINO, Calif., Feb. 12, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for POSIDUR((TM)) (SABER(®)-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia. Based on its review, the FDA has determined that they cannot approve the NDA in its present form,...

2014-02-12 08:28:31

LITTLE ROCK, AR, Feb. 12, 2014 /CNW/ - (TSX-V:VBI) - Vivione Biosciences Inc. ("Vivione") is pleased to announce the signing of a Memorandum of Understanding ("MOU") with South Korean biotech company, AriBio, Inc. ("AriBio"). This strategic alliance is anticipated to combine the strengths of Vivione in the areas of rapid diagnostics and its new in silico compound modeling technology ("Molecular Design") with AriBio's substantial experience in drug design and testing. The alliance...

2014-02-11 23:20:32

Avomeen Analytical Services recently released a detailed outline of the chemical tests necessary to successfully complete the drug development process from a fresh viewpoint. (PRWEB) February 11, 2014 While there are many resources that exist to outline the drug development process from both an FDA requirement standpoint and a clinical trial perspective, this article outlines these processes through a new light. “Utilizing Chemical Analysis throughout the Drug Development Process” is...

2014-02-11 16:23:20

DUBLIN, February 11, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/s3bn4c/patch_pump_drug) has announced the addition of the "Patch Pump Drug Delivery Systems to 2018" [http://www.researchandmarkets.com/research/s3bn4c/patch_pump_drug ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Devices, Drugs, Markets, and Forecasts Patch pumps are the convergence of several technologies...

2014-02-11 08:32:03

Company adds Scott Biller to its Scientific Advisory Board NEW HAVEN, Conn., Feb. 11, 2014 /PRNewswire/ -- Arvinas Inc., a biotechnology company creating a new class of drugs based on protein degradation, today announced the appointment of Jim Winkler, Ph.D., to the position of Chief Scientific Officer. Dr. Winkler will be responsible for the discovery and development of potential drug compounds that will target specific disease-driving proteins for degradation. In addition, the...

2014-02-10 23:26:09

Many of the problems uncovered during inspections are common and recurring problems within the drug and device industry. In this webinar, Dr. David Lim, an accomplished former FDA official with CDRH and pharma executive, will describe the 29 problems that continually show up in 483s and warning letters, and explain why and how the FDA focuses on them. Falls Church, VA (PRWEB) February 10, 2014 Create an Inspection Readiness Gap Analysis: How to Avoid the FDA’s Top 29 483 Citations...

2014-02-10 16:26:51

NEW YORK, Feb. 10, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of The Medicines Company ("Medicines" or the "Company")(NasdaqGS: MDCO). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. The investigation concerns whether Medicines and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On Monday, February 10,...